Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and DisordersPRNewsWire • 11/03/22
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid ShortfallInvestors Business Daily • 11/03/22
Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product AwardPRNewsWire • 10/28/22
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) InjectionPRNewsWire • 10/21/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical CancerZacks Investment Research • 10/17/22
Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with RegeneronBusiness Wire • 10/17/22
Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical CancerPRNewsWire • 10/14/22
EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority ReviewPRNewsWire • 10/12/22
Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years OldPRNewsWire • 10/11/22
These Are The Five Best And Worst Performing Large-Cap Stocks In September 202224/7 Wall Street • 10/10/22
Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022PRNewsWire • 10/04/22
Regeneron (REGN) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research • 10/04/22
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAOPRNewsWire • 09/30/22